Outcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one human leukocyte antigen mismatched related donors using HLA typing at 10 loci.
Outcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one human leukocyte antigen mismatched related donors using HLA typing at 10 loci.
复制标题
使用来自匹配的非相关供体的同种异体造血干细胞移植治疗的骨髓恶性肿瘤患者的结果与使用 10 个位点的 HLA 分型的一种人类白细胞抗原不匹配的相关供体进行比较。
DOI：
10.1016/j.bbmt.2010.10.017
复制
发表时间：
2011-06
影响因子：
4.3
通讯作者：
de Lima, Marcos
中科院分区：
文献类型：
--
作者：
Ciurea, Stefan O.;Saliba, Rima M.;Rondon, Gabriela;Patah, Paliana A.;Aung, Fleur;Cano, Pedro;Andersson, Borje S.;Kebriaei, Partow;Papat, Uday;Fernandez-Vina, Marcelo;Champlin, Richard E.;de Lima, Marcos
关键词：
大多数造血干细胞移植（HSCT）的候选人缺乏人类白细胞抗原（HLA）相同的同胞供体。一些患者可能有一个相关的供体，他们在1个抗原/等位基因上不匹配。目前尚不清楚这种匹配是否优于匹配的无关供体（MUD）。我们评估了所有28例通过HLA-A、-B、-C、-DRB 1和-DQB 1的高分辨率HLA分型确定的单一HLA抗原/等位基因错配的患者的结局（生存、复发、非复发死亡率[NRM]），以及所有318例在同一机构接受10/10 MUD移植的骨髓恶性肿瘤患者的结局。总体而言，1抗原/等位基因错配相关供体治疗患者的结局显著差于MUD，主要是因为NRM增加。1-抗原/等位基因不匹配的亲属供者和MUD移植受者的3年总生存率分别为19%和45%（P = 0.007），NRM率分别为40%和26%（P = 0.05）。I类错配患者的OS似乎比II类错配患者差。在不匹配的亲属供者组中，移植物排斥反应的发生率更高（P =.02）。这些结果表明，MUD的移植结果优于1抗原/等位基因不匹配的相关供体。
Most candidates for hematopoietic stem cell transplantation (HSCT) lack a human leukocyte antigen (HLA)-identical sibling donor. Some patients may have a related donor with whom they are mismatched at 1 antigen/allele. It is not known whether such a match is preferable to a matched unrelated donor (MUD). We evaluated the outcomes (survival, relapse, nonrelapse mortality [NRM]) of all 28 patients with a single HLA antigen/allele mismatch identified through high-resolution HLA typing at HLA-A, -B, -C, -DRB1, and -DQB1, and all 318 patients with myeloid malignancies who received transplants from a 10/10 MUD treated during the same period of time at a single institution. Overall, outcomes for patients treated from a 1-antigen/allele mismatch related donor were significantly worse than from a MUD, primarily because of increased NRM. Overall survival (OS) rates at 3 years for 1-antigen/allele mismatched related donor and MUD transplant recipients were 19% and 45% (P =.007), and NRM rates were 40% and 26% (P =.05), respectively. Patients with class I mismatches appeared to have poorer OS than did patients with class II mismatches. A higher incidence of graft rejection was identified in the mismatched related donor group (P =.02). These results indicate that transplant outcomes are better with a MUD than with a 1 antigen/allele-mismatched related donor.
登录
查看更多内容
影响因子：
20.3
作者：
Weisdorf, DJ;Anasetti, C;McGlave, P
通讯作者：
McGlave, P
影响因子：
2.7
作者：
Leung, WH;Turner, V;Bowman, LC
通讯作者：
Bowman, LC
影响因子：
158.5
作者：
Petersdorf, EW;Hansen, JA;Anasetti, C
通讯作者：
Anasetti, C
影响因子：
1.9
作者：
PRENTICE, RL;KALBFLEISCH, JD;BRESLOW, NE
通讯作者：
BRESLOW, NE
影响因子：
20.3
作者：
Morishima, Y;Sasazuki, T;Kodera, Y
通讯作者：
Kodera, Y